Skip to content
  • Français
  • English
Seabelife
  • Home
  • News
  • Indications
  • Technology
  • Team
  • Scientific Publications
  • Contact
  • FR
Seabelife
  • Home
  • News
  • Indications
  • Technology
  • Team
  • Scientific Publications
  • Contact
  • FR

SeaBeLife Biotech raises € 1 million to carry onits drug developments targeting regulated cell death

28 May 2021

SeaBeLife Biotech raises € 1 million to carry onits drug developments targeting regulated cell death. Roscoff, May 17th, 2021. SeaBeLife, … Lire la suite

Categories Press Release

SeaBeLife Biotech raises € 1.5 million to develop drugs targeting regulated cell death.

9 February 202119 June 2020

SeaBeLife Biotech raises € 1.5 million to develop drugs targeting regulated cell death. Roscoff, June 15, 2020. SeaBeLife, a pharmaceutical … Lire la suite

Categories Press Release
Newer posts
← Previous Page1 Page2
Charger + d'articles

Categories

  • News (4)
  • Press Release (8)

Recent Posts

  • SeaBeLife welcomes Professor Eric Souied to its scientific committee 
  • Cell Death Discovery article confirms that sibiriline uniquely targets and inhibits two key forms of programmed cell death: necroptosis and ferroptosis
  • SeaBeLife enters into joint development agreement with Unither Pharmaceuticals to formulate and produce ophthalmic drug candidate
  • SeaBeLife secures €2 million – This funding will help fast-track the launch of clinical trials in dry AMD and severe acute hepatitis programs
  • Dry AMD: SeaBeLife achieves highly promising preclinical efficacy results for SBL03, without injections into eye
Contact Presse

SeaBeLife is a biotechnology company developing innovative molecules that simultaneously target two major pathways of regulated cell death to meet major unmet medical needs in acute, rare or chronic indications.

Partenaires

  • Contact
  • Investors
  • Recrutement
  • Français

legals

© SeaBeLife - 2026